Key Points
- Major shareholder Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals at an average price of $3.23 on June 30, increasing its stake by 9.40% to 78,597 shares worth about $253,868.
- The same insider also purchased 25,836 shares on June 29 at an average price of $3.44, indicating continued buying in SHPH.
- Shuttle Pharmaceuticals shares were trading around $3.40, near their 52-week low of $2.90, while the company remains small with a market cap of just $2.18 million and analysts still rate the stock a Sell.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH - Get Free Report) major shareholder Financial Lp Hrt purchased 6,755 shares of the business's stock in a transaction dated Tuesday, June 30th. The stock was purchased at an average price of $3.23 per share, for a total transaction of $21,818.65. Following the completion of the acquisition, the insider owned 78,597 shares of the company's stock, valued at approximately $253,868.31. This represents a 9.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.44 per share, with a total value of $88,875.84.
Shuttle Pharmaceuticals Stock Performance
NASDAQ:SHPH opened at $3.40 on Thursday. The stock has a 50-day simple moving average of $5.93 and a 200 day simple moving average of $10.74. Shuttle Pharmaceuticals Holdings, Inc. has a 52-week low of $2.90 and a 52-week high of $55.90. The company has a market cap of $2.18 million, a PE ratio of -0.07 and a beta of 0.29.
Shuttle Pharmaceuticals (NASDAQ:SHPH - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.
Hedge Funds Weigh In On Shuttle Pharmaceuticals
A number of large investors have recently modified their holdings of SHPH. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $124,000. Boothbay Fund Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at about $37,000. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the fourth quarter worth about $26,000. Finally, Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the third quarter worth about $357,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a "sell (e)" rating to a "sell (e+)" rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of "Sell".
Check Out Our Latest Analysis on SHPH
Shuttle Pharmaceuticals Company Profile
(
Get Free Report)
Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
